Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Emerald Resources NL
ASX:EMR
|
AU |
|
Zhejiang Goldensea Hi-Tech Co Ltd
SSE:603311
|
CN |
|
China United Network Communications Ltd
SSE:600050
|
CN |
|
I
|
Interworld Digital Ltd
BSE:532072
|
IN |
|
Infracommerce CXAAS SA
BOVESPA:IFCM3
|
BR |
|
Shaanxi Heimao Coking Co Ltd
SSE:601015
|
CN |
|
A
|
Allied Copper Corp
XTSX:CPR
|
CA |
|
Terilogy Co Ltd
TSE:3356
|
JP |
|
Formosa Plastics Corp
TWSE:1301
|
TW |
|
W
|
Wuxi Online Offline Communication Information Technology Co Ltd
SZSE:300959
|
CN |
|
Z
|
Zuger Kantonalbank
SIX:ZUGER
|
CH |
|
UCO Bank
NSE:UCOBANK
|
IN |
|
Vonex Ltd
ASX:VN8
|
AU |
|
K
|
Kaiser China Culture Co Ltd
SZSE:002425
|
CN |
|
Graph Blockchain Inc
OTC:REGRF
|
CA |
Novan Inc
Total Liabilities
Novan Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Total Liabilities
$85.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Liabilities
$117.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Liabilities
$71.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
15%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Liabilities
$121.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Liabilities
$84.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Liabilities
$85.9B
|
CAGR 3-Years
30%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Total Liabilities?
Total Liabilities
85.7m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Total Liabilities amounts to 85.7m USD.
What is Novan Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
30%
Over the last year, the Total Liabilities growth was 69%. The average annual Total Liabilities growth rates for Novan Inc have been 17% over the past three years , 30% over the past five years .
